Physician

Alexandru Filip Kimel, M.D.

According to 2025 Medicare claims, Alexandru Kimel, M.D. (NPI: 1992940860) practices rheumatology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES OF NORTH JERSEY (NPI: 1699871442; TIN: 222322338) and primary practice location at 07666-3521. Kimel is affiliated with the NewYork Quality Care (ACO ID: A2571), participating under the MSSP model.

Kimel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 524 traditional Medicare patients, billed 121,670 HCPCS/CPT codes, and received $1,909,664 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,378 prescription claims across 418 beneficiaries totaling $2,357,916 in drug costs, led by Humira Pen (Adalimumab). 2016 DME data shows 11 claims. Open Payments data shows 19 records totaling $386. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $968,135 to $2,357,916. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	336	32,095	$895,332
2016	425	53,622	$1,249,225
2017	440	66,706	$1,754,135
2018	424	53,790	$1,485,237
2019	408	51,284	$1,316,722
2020	416	60,232	$1,462,120
2021	435	74,194	$1,590,411
2022	461	86,516	$1,336,605
2023	511	88,966	$1,447,953
2024	524	121,670	$1,909,664

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,634	$968,135
2016	275	1,758	$851,071
2017	307	1,884	$1,016,726
2018	305	1,712	$1,043,809
2019	293	1,827	$1,088,985
2020	322	1,815	$1,166,387
2021	385	2,084	$1,459,963
2022	381	2,319	$2,336,523
2023	401	2,332	$2,487,439
2024	418	2,378	$2,357,916

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	11	$124
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	479	1,168	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	319	554	$13
80048	Blood test, basic group of blood chemicals (calcium, total)	285	585	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	284	593	$8
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	284	586	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira Pen	Adalimumab	42	1,176	$312,627
Humira(Cf) Pen	Adalimumab	34	952	$237,816
Rinvoq	Upadacitinib	18	780	$154,997
Prolia	Denosumab	84	15,120	$135,689
Simponi	Golimumab	17	476	$93,838

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$386	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexandru Filip Kimel, M.D.?

Tedicare shows public-source Medicare data for Alexandru Filip Kimel, M.D. (NPI 1992940860), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexandru Filip Kimel, M.D. have ACO affiliation data?

Alexandru Filip Kimel, M.D. is shown with ACO affiliation data for NewYork Quality Care (MSSP, ACO ID A2571).

What billing organization is linked to Alexandru Filip Kimel, M.D.?

Alexandru Filip Kimel, M.D. is linked to RHEUMATOLOGY ASSOCIATES OF NORTH JERSEY (billing NPI 1699871442) in the available physician profile data.

Does Alexandru Filip Kimel, M.D. have Open Payments data?

Alexandru Filip Kimel, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.